Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2600-2608

  O'Sullivan, Ciara C ^a   Bradbury, Ian ^b   Campbell, Christine ^b   Spielmann, Marc ^c   Perez, Edith A ^d   Joensuu, Heikki ^e   Costantino, Joseph P ^f   Delaloge, Suzette ^c   Rastogi, Priya ^f   Zardavas, Dimitrios ^g   Ballman, Karla V ^h   Holmes, Eileen ^b   De Azambuja, Evandro ⁱ   Piccart Gebhart, Martine ⁱ   Zujewski, Jo Anne ^a   Gelber, Richard D ^j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Tweedle Medical Practice   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d MAYO CLINIC   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g Breast International Group ^*  (United States)

^h MAYO CLINIC   (United States)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SIZE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW (TOPIC); ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; ENZYMOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84940512225     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.8620     Document Type: Article

References (36)

1. American Cancer Society: What are the key statistics about breast cancer? http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49:1374-1403, 2013
3. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. 2008 San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 62)
5. Perez EA, Dueck AC, McCullough AE, et al: Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 31:2115-2122, 2013
6. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
7. Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
8. Joensuu H, Bono P, Kataja V, et al: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 27:5685-5692, 2009
9. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet 382:1021-1028, 2013
10. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
11. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
12. Jelovac D, Wolff AC: The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 13:230-239, 2012
13. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
14. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
15. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
16. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
17. Zardavas D, Cameron D, Krop I, et al: Beyond trastuzumab and lapatinib: New options for HER2-positivebreastcancer.http://meetinglibrary.asco.org/content/237-132
18. Zardavas D, Bozovic-Spasojevic I, de Azambuja E: Dual human epidermal growth factor receptor 2 blockade: Another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer. Curr Opin Oncol 24:612-622, 2012
19. Saini KS, Azim HA Jr, Metzger-Filho O, et al: Beyond trastuzumab: New treatment options for HER2-positive breast cancer. Breast 20:S20-S27, 2011 (suppl 3)
20. ClinicalTrials.gov: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. APHINITY trial. https://clinicaltrials.gov/ct2/show/NCT01358877
21. ClinicalTrials.gov: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. https://clinicaltrials.gov/ct2/show/NCT00490139
22. ClinicalTrials.gov: NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study. https://clinicaltrials.gov/ct2/show/NCT00553358
23. Swain SM Baselga J, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015
24. Ellis MJ: HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy. J Natl Cancer Inst 106:8, 2014.
25. Vaz-Luis I, Ottesen RA, Hughes ME, et al: Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. J Clin Oncol 32:2142-2150, 2014
26. Burstein HJ, Winer EP: Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673, 2009
27. Joerger M, Thürlimann B, Huober J: Small HER2-positive, node-negative breast cancer: Who should receive systemic adjuvant treatment? Ann Oncol 22:17-23, 2011
28. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
29. Tovey SM, Brown S, Doughty JC, et al: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 100:680-683, 2009
30. Joensuu H, Isola J, Lundin M, et al: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 9:923-930, 2003
31. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
32. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
33. Tolaney SM, Barry WT, Dang CT, et al: Adjuvant paclitaxel for node-negative, HER2-positive breast cancer. N Engl J Med 372:134-141, 2015
34. O'Sullivan CC, Holmes E, Spielmann M, et al: The prognosis of small HER2-positive breast cancers: A meta-analysis of the randomized trastuzumab trials. 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013 (abstr S6-03)
35. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
36. ClinicalTrials.gov: T-DM1 vs paclitaxel/trastuzumab for breast (ATEMPT Trial). https://clinicaltrials.gov/ct2/show/NCT01853748